Corteva (NYSE:CTVA) Releases FY 2026 Earnings Guidance

Key Points

• FY2026 EPS guidance: Corteva issued an EPS range of 3.450–3.700, roughly in line with the consensus of 3.650, but notably provided no revenue guidance (consensus ~$18.1B).
• Market reaction and dividend: Shares rose about 2.7% to $83.91 after the update, and the company announced a quarterly dividend of $0.18 ($0.72 annualized) with an ex-dividend date of June 1 and a yield of ~0.9%.
• Recent results and analyst view: Corteva's most recent quarter delivered $0.22 EPS (in line) but missed revenue at $3.91B, and analysts hold a "Moderate Buy" consensus with an average price target of $86.38.

Corteva (NYSE:CTVA - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.450-3.700 for the period, compared to the consensus estimate of 3.650. The company issued revenue guidance of -, compared to the consensus revenue estimate of $18.1 billion.

Corteva Stock Up 2.7%

CTVA stock traded up $2.22 during trading on Tuesday, reaching $83.91. The stock had a trading volume of 5,008,023 shares, compared to its average volume of 3,983,275. Corteva has a one year low of $60.53 and a one year high of $85.63. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The company's 50 day moving average is $80.39 and its two-hundred day moving average is $72.18. The company has a market capitalization of $56.33 billion, a price-to-earnings ratio of 53.11, a P/E/G ratio of 2.77 and a beta of 0.59.

Corteva (NYSE:CTVA - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting analysts' consensus estimates of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the firm earned $0.32 EPS. The company's revenue was down 1.7% compared to the same quarter last year. Equities research analysts forecast that Corteva will post 3.62 EPS for the current year.

Corteva Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Monday, June 1st will be given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Monday, June 1st. Corteva's dividend payout ratio is currently 45.57%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Corteva from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. The Goldman Sachs Group increased their target price on shares of Corteva from $88.00 to $96.00 and gave the company a "buy" rating in a research report on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Corteva from $85.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, February 5th. Wells Fargo & Company upped their price target on shares of Corteva from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Tuesday, April 21st. Finally, JPMorgan Chase & Co. cut shares of Corteva from an "overweight" rating to a "neutral" rating and upped their price target for the company from $75.00 to $77.00 in a research note on Thursday, February 5th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $86.38.

Insider Activity at Corteva

In other Corteva news, insider Brian Titus sold 8,311 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the sale, the insider directly owned 8,090 shares in the company, valued at $619,289.50. This represents a 50.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.15% of the company's stock.

Institutional Trading of Corteva

Several institutional investors and hedge funds have recently bought and sold shares of CTVA. Brighton Jones LLC lifted its stake in Corteva by 307.2% in the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company's stock worth $888,000 after purchasing an additional 11,760 shares in the last quarter. Woodline Partners LP lifted its stake in Corteva by 40.3% in the 1st quarter. Woodline Partners LP now owns 57,919 shares of the company's stock worth $3,645,000 after purchasing an additional 16,644 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Corteva by 62.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,559 shares of the company's stock worth $191,000 after purchasing an additional 980 shares in the last quarter. Cresset Asset Management LLC raised its stake in Corteva by 2.6% in the second quarter. Cresset Asset Management LLC now owns 7,063 shares of the company's stock valued at $526,000 after purchasing an additional 181 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in Corteva during the second quarter valued at approximately $1,464,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.